Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED
ESMO Open. 2022 Sep 23;7(5):100585. doi: 10.1016/j.esmoop.2022.100585
A comprehensive investigation of histotype-specific microRNA and their variants in Stage I epithelial ovarian cancers.
Velle A
Int J Cancer. 2023 Jan 17;152(9):1989-2001. doi: 10.1002/ijc.34408
Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity.
Mantovani A
Int J Cancer. 22(6):741-6.
Regulation of the macrophage content of neoplasms by chemoattractants.
Bottazzi B
Science. 220(4593):210-2.
Prostacyclin synthesis induced in vascular cells by interleukin-1.
Rossi V
Science. 229(4709):174-6.
Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate.
Bussolino F
Nature. 337(6206):471-3.
Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.
Colotta F
Science. 261(5120):472-5.
Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist.
Muzio M
J Exp Med. 182(2):623-8.
Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells.
Colotta F
J Exp Med. 181(6):2181-6.
Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface “receptor” with anti-interleukin-1 function.
Re F
J Exp Med. 183(4):1841-50.